Dae-Yeul Yu Selected Research

hepatitis B virus X protein

1/2020	Relevance of reactive oxygen species in liver disease observed in transgenic mice expressing the hepatitis B virus X protein.
1/2016	IGF-II induced by hepatitis B virus X protein regulates EMT via SUMO mediated loss of E-cadherin in mice.
9/2014	Hepatitis B virus X protein specially regulates the sialyl lewis a synthesis among glycosylation events for metastasis.
10/2013	The Effect of Metformin Treatment on CRBP-I Level and Cancer Development in the Liver of HBx Transgenic Mice.
5/2013	iNOS promotes HBx-induced hepatocellular carcinoma via upregulation of JNK activation.
1/2011	Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling.
10/2010	HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway.
11/2009	Proteomic analysis of liver tissue from HBx-transgenic mice at early stages of hepatocarcinogenesis.
2/2004	Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha.
10/2003	Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dae-Yeul Yu Research Topics

Disease

36	Neoplasms (Cancer) 05/2022 - 01/2004
27	Hepatocellular Carcinoma (Hepatoma) 12/2020 - 09/2002
11	Carcinogenesis 05/2022 - 11/2009
9	Inflammation (Inflammations) 10/2021 - 09/2002
7	Liver Neoplasms (Liver Cancer) 01/2016 - 09/2002
6	Infections 12/2020 - 01/2002
4	Liver Diseases (Liver Disease) 01/2020 - 09/2002
3	Lung Neoplasms (Lung Cancer) 10/2021 - 05/2015
3	Neoplasm Metastasis (Metastasis) 07/2019 - 10/2003
3	Hypoxia (Hypoxemia) 04/2015 - 10/2003
2	Hepatitis B 01/2019 - 01/2011
2	Shock 08/2018 - 03/2007
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 05/2015
2	Atherosclerosis 01/2018 - 09/2011
2	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2017 - 01/2011
2	Virus Diseases (Viral Diseases) 02/2016 - 12/2012
2	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2013 - 06/2005
2	Breast Neoplasms (Breast Cancer) 01/2013 - 10/2006
2	Adenoma (Adenomas) 07/2010 - 01/2009
2	Carcinoma (Carcinomatosis) 10/2009 - 01/2009
1	Adenocarcinoma of Lung 01/2018
1	Colorectal Neoplasms (Colorectal Cancer) 01/2017
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 02/2016
1	Colonic Neoplasms (Colon Cancer) 02/2016
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 02/2016
1	Hepatomegaly 01/2016
1	Thrombosis (Thrombus) 05/2015
1	Melanoma (Melanoma, Malignant) 01/2015
1	Lewis Lung Carcinoma 01/2015
1	B-Cell Lymphoma (Lymphoma, B Cell) 02/2014

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 05/2022 - 02/2004
13	PeroxiredoxinsIBA 01/2019 - 03/2007
12	hepatitis B virus X proteinIBA 01/2020 - 09/2002
10	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 06/2005
9	EnzymesIBA 10/2021 - 06/2005
6	AntioxidantsIBA 01/2017 - 06/2005
5	AntigensIBA 01/2019 - 06/2010
4	LigandsIBA 10/2021 - 01/2004
4	CytokinesIBA 05/2019 - 09/2002
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2009
4	AlbuminsIBA 01/2015 - 11/2005
3	Pharmaceutical PreparationsIBA 01/2020 - 07/2010
3	AutoantibodiesIBA 01/2019 - 06/2010
3	LipidsIBA 01/2018 - 05/2007
3	Histones (Histone)IBA 04/2016 - 10/2006
2	Androgen Receptors (Androgen Receptor)IBA 12/2020 - 11/2014
2	Gefitinib (Iressa)FDA Link 01/2019 - 05/2015
2	MicroRNAs (MicroRNA)IBA 01/2018 - 04/2016
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2017 - 02/2014
2	CateninsIBA 01/2017 - 01/2011
2	Cadherins (E-Cadherin)IBA 01/2016 - 01/2009
2	CaspasesIBA 02/2014 - 07/2009
2	p38 Mitogen-Activated Protein KinasesIBA 06/2013 - 07/2009
2	Peptides (Polypeptides)IBA 01/2013 - 06/2010
2	DNA (Deoxyribonucleic Acid)IBA 02/2012 - 12/2010
2	Trans-Activators (Trans-Acting Factor)IBA 01/2011 - 09/2002
2	2'-benzoyloxycinnamaldehydeIBA 01/2009 - 01/2006
2	Biological ProductsIBA 04/2008 - 05/2005
2	Interleukin-18 (Interleukin 18)IBA 04/2008 - 09/2002
2	AntibodiesIBA 04/2008 - 09/2002
2	PPAR gammaIBA 05/2007 - 01/2004
1	Adenosine Monophosphate (AMP)IBA 05/2022
1	Interleukin-6 (Interleukin 6)IBA 10/2021
1	Leukotriene B4IBA 10/2021
1	Cardiac GlycosidesIBA 12/2020
1	Phosphotransferases (Kinase)IBA 12/2020
1	bufalinIBA 12/2020
1	LectinsIBA 10/2020
1	Monoclonal AntibodiesIBA 10/2020
1	ubiquitin carrier proteinsIBA 07/2019
1	Prokaryotic Initiation Factor-3IBA 01/2019
1	ChromatinIBA 01/2018
1	Jiedu Xiaozheng YinIBA 01/2018
1	TankyrasesIBA 01/2017
1	Enhancer of Zeste Homolog 2 ProteinIBA 04/2016
1	Lysine (L-Lysine)FDA Link 04/2016
1	Morphine (MS Contin)FDA LinkGeneric 02/2016
1	InterleukinsIBA 02/2016
1	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2016
1	Epithelial Cell Adhesion MoleculeIBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	Transcription Factors (Transcription Factor)IBA 01/2016
1	Nuclear Proteins (Protein, Nuclear)IBA 10/2015
1	Antineoplastic Agents (Antineoplastics)IBA 05/2015
1	CollagenIBA 05/2015
1	Lactic Acid (Lactate)FDA LinkGeneric 04/2015
1	LatexIBA 01/2015
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2015
1	Coloring Agents (Dyes)IBA 01/2015
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 01/2015
1	Lewis Blood Group AntigensIBA 09/2014
1	GlycosyltransferasesIBA 09/2014
1	CA-19-9 Antigen (CA 19-9 Antigen)IBA 09/2014
1	Small Interfering RNA (siRNA)IBA 09/2014
1	Caspase 8 (Caspase-8)IBA 02/2014
1	dimethyl sulfone (methylsulfonylmethane)IBA 02/2014

Therapy/Procedure

7	Therapeutics 01/2018 - 06/2011
2	Intravenous Injections 02/2012 - 03/2007
1	Drug Therapy (Chemotherapy) 01/2018
1	Analgesia 02/2016